Satellos Bioscience Inc. (NASDAQ:MSLE) Receives $15.50 Consensus Price Target from Analysts

Satellos Bioscience Inc. (NASDAQ:MSLE) has received a consensus rating of “Hold” from the five brokerages that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $15.50.

A number of equities research analysts have issued reports on the company. Weiss Ratings assumed coverage on Satellos Bioscience in a research note on Wednesday, February 11th. They issued a “sell (d-)” rating on the stock. Wall Street Zen cut Satellos Bioscience to a “strong sell” rating in a research note on Saturday, March 14th. Cantor Fitzgerald assumed coverage on Satellos Bioscience in a research note on Wednesday, March 11th. They issued an “overweight” rating on the stock. Zacks Research upgraded Satellos Bioscience to a “hold” rating in a research note on Tuesday, February 10th. Finally, Leerink Partners assumed coverage on Satellos Bioscience in a research note on Monday. They issued an “outperform” rating and a $20.00 target price on the stock.

Satellos Bioscience Trading Up 11.8%

Shares of MSLE opened at $6.25 on Monday. Satellos Bioscience has a 12-month low of $4.53 and a 12-month high of $13.39. The firm has a market cap of $96.63 million, a P/E ratio of -4.03 and a beta of 1.37.

Satellos Bioscience (NASDAQ:MSLE) last announced its quarterly earnings data on Friday, March 27th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.11).

Satellos Bioscience Company Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.